Patient Compliance and Persistency
November 18-19, 2004 London, UK
Visit the conference website for more information and to register.
Hear What Some of the Hundreds of Executives Who Have Benefited From CBI’s Patient Compliance Conferences Had to Say:
“I always come away with insights that I can apply to my work and increase both consumer/patient experience and competitive advantage.”
— Vincent DiFabritus, Senior Design Manager, Procter & Gamble
“I appreciated the mix of viewpoints from the presentations It was very helpful in understanding the scope of this issue.”
— Russ Allinson, Senior Vice President, Pharmacy, Priority Healthcare
“I enjoyed receiving case study data that showed how to track patient compliance and prove ROI.”
— Cathy Veum, Vice President, Covance
“A program that brings together the many tools, services and products that pharma can choose to address and improve medication adherence with their brand.”
— Bill Sharpless, Manager, Compliance Packaging, Honeywell
“CBI is at the forefront in addressing the patient compliance issue for the industry. CBI’s Patient Compliance and Persistency Forum has grown in attendance and content with each event. This is the conference to attend over the next few years.”
— Grant Corbett, Principal, Behavior Change Solutions
“This CBI conference provided an outstanding opportunity to hear from some of the leading players from industry, agencies and vendors to exchange ideas and opportunities in an attractive engaging environment.”
— Jay Bernhardt Ph.D., MPH, Behavioral Sciences and Health Education, Emory University
CBI’s Patient Compliance and Persistency conference, 18th and 19th November, 2004 in London provides insights into the financial implications of patient noncompliance and the ROI of compliance programs. When pharmaceutical companies implement compliance programs in order to build awareness and education of medical conditions and the benefits of taking medications, they will make more money on the sale of the medications than what they are spending on these programs.
The goal of this conference is to examine compliance programs established by companies such as: F. Hoffman La Roche Ltd., Abbott GmbH & Co. KG, H. Lundbeck A/S, Roche Products Limited and Schering Corporation, as well as discuss strategies and initiatives to educate patients on their medical conditions and the benefits of taking their drugs correctly which aid pharmaceutical companies in improving the ROI of such programs within their legal limits from country to country.
The types of programs that are now in existence, their effectiveness and ROI, as well as behavioral studies as to what factors influence a patient not to fill or comply with a prescription are discussed in depth. Don’t miss your chance to hear a patient’s perspective through patient groups and associations that help build disease management communities.